An HIV envelope gp120-fc fusion protein elicits effector antibody responses in rhesus macaques

Clinical and Vaccine Immunology

Volumn 24, Issue 6, 2017, Pages

  Shubin, Zhanna ^a   Li, Weizhong ^b   Poonia, Bhawna ^a   Ferrari, Guido ^c   LaBranche, Celia ^c   Montefiori, David ^c   Zhu, Xiaoping ^b   Pauza, C David ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b University of Maryland   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fc gamma receptor; HIV envelope gp120; Immune complex; Immunization; Vaccine

Indexed keywords

ANTISERUM; CD4 ANTIGEN; FC RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE GP120 FC FUSION PROTEIN; HYBRID PROTEIN; MONOMER; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN; GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN FC FRAGMENT; NEUTRALIZING ANTIBODY; PROTEIN BINDING; RECOMBINANT VACCINE;

ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; IMMUNOCOMPETENT CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; VIRUS ENVELOPE; ANIMAL; ANTIBODY PRODUCTION; BLOOD; GENETICS; IMMUNOLOGY; METABOLISM;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CD4 ANTIGENS; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; IMMUNOGLOBULIN FC FRAGMENTS; MACACA MULATTA; MALE; PROTEIN BINDING; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC;

EID: 85020170186     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00028-17     Document Type: Article

References (36)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH, MOPH-TAVEG Investigators. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209-2220. https://doi.org/10.1056/NEJMoa0908492.
2. Burton DR, Hangartner L. 2016. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu Rev Immunol 34:635-659. https://doi.org/10.1146/annurev-immunol-041015-055515.
3. Sliepen K, Sanders RW. 2016. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies. Expert Rev Vaccines 15: 349-365. https://doi.org/10.1586/14760584.2016.1129905.
4. Kong L, Sattentau QJ. 2012. Antigenicity and immunogenicity in HIV-1 antibody-based vaccine design. J AIDS Clin Res S8:3.
5. Zaharatos GJ, Yu J, Pace C, Song Y, Vasan S, Ho DD, Huang Y. 2011. HIV-1 and influenza antigens synthetically linked to IgG2a Fc elicit superior humoral responses compared to unmodified antigens in mice. Vaccine 30:42-50. https://doi.org/10.1016/j.vaccine.2011.10.056.
6. Qi Z, Pan C, Lu H, Shui Y, Li L, Li X, Xu X, Liu S, Jiang S. 2010. A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice. Biochem Biophys Res Commun 398: 506-512. https://doi.org/10.1016/j.bbrc.2010.06.109.
7. Chen H, Xu X, Jones IM. 2007. Immunogenicity of the outer domain of a HIV-1 clade C gp120. Retrovirology 4:33. https://doi.org/10.1186/1742-4690-4-33.
8. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. 1980. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 26:171-176. https://doi.org/10.1002/ijc.2910260208.
9. Fouts TR, Tuskan R, Godfrey K, Reitz M, Hone D, Lewis GK, DeVico AL. 2000. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J Virol 74:11427-11436. https://doi.org/10.1128/JVI.74 .24.11427-11436.2000.
10. Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin C-l, Bilska M, Greene KM, Gao H, Todd CA, Ozaki DA, Seaman MS, Mascola JR, Montefiori DC. 2014. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods 409:131-146. https://doi.org/10.1016/j.jim.2013.11.022.
11. Pollara J, Hart L, Brewer F, Pickeral J, Packard BZ, Hoxie JA, Komoriya A, Ochsenbauer C, Kappes JC, Roederer M, Huang Y, Weinhold KJ, Tomaras GD, Haynes BF, Montefiori DC, Ferrari G. 2011. Highthroughput quantitative analysis of HIV-1 and SIV-specific ADCCmediating antibody responses. Cytometry A 79:603-612. https://doi .org/10.1002/cytoa.21084.
12. Kumar A, Lifson JD, Silverstein PS, Jia F, Sheffer D, Li Z, Narayan O. 2000. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses. Virology 274:149-164. https://doi.org/10.1006/viro.2000.0444.
13. Seaman MS, Xu L, Beaudry K, Martin KL, Beddall MH, Miura A, Sambor A, Chakrabarti BK, Huang Y, Bailer R, Koup RA, Mascola JR, Nabel GJ, Letvin NL. 2005. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 79:2956-2963. https://doi.org/10.1128/JVI.79 .5.2956-2963.2005.
14. Lai L, Kwa SF, Kozlowski PA, Montefiori DC, Nolen TL, Hudgens MG, Johnson WE, Ferrari G, Hirsch VM, Felber BK, Pavlakis GN, Earl PL, Moss B, Amara RR, Robinson HL. 2012. SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine 30: 1737-1745. https://doi.org/10.1016/j.vaccine.2011.12.026.
15. Li J, Valentin A, Kulkarni V, Rosati M, Beach RK, Alicea C, Hannaman D, Reed SG, Felber BK, Pavlakis GN. 2013. HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine 31:3747-3755. https://doi.org/10.1016/j.vaccine.2013.04.037.
16. DeVico A, Fouts T, Lewis GK, Gallo RC, Godfrey K, Charurat M, Harris I, Galmin L, Pal R. 2007. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci U S A 104:17477-17482. https://doi.org/10.1073/pnas.0707399104.
17. Shingai M, Donau OK, Plishka RJ, Buckler-White A, Mascola JR, Nabel GJ, Nason MC, Montefiori D, Moldt B, Poignard P, Diskin R, Bjorkman PJ, Eckhaus MA, Klein F, Mouquet H, Cetrulo Lorenzi JC, Gazumyan A, Burton DR, Nussenzweig MC, Martin MA, Nishimura Y. 2014. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med 211:2061-2074. https://doi.org/10.1084/jem.20132494.
18. McCoy LE, Weiss RA. 2013. Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med 210:209-223. https://doi.org/10.1084/jem .20121827.
19. Kovacs JM, Nkolola JP, Peng H, Cheung A, Perry J, Miller CA, Seaman MS, Barouch DH, Chen B. 2012. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci U S A 109:12111-12116. https://doi.org/10.1073/pnas.1204533109.
20. Anonymous. 2003. VaxGen vaccine trial fails the test but may offer insights. AIDS Alert 18:41, 43-45.
21. Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, Khamboonruang C, Thongcharoen P, Morgan P, Benenson M, Paris RM, Chiu J, Adams E, Francis D, Gurunathan S, Tartaglia J, Gilbert P, Stablein D, Michael NL, Kim JH. 2012. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 12:531-537. https://doi.org/10.1016/S1473-3099(12)70088-9.
22. Brady LJ. 2005. Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens. Infect Immun 73: 671-678. https://doi.org/10.1128/IAI.73.2.671-678.2005.
23. Bournazos S, Ravetch JV. 2015. Fc receptor pathways during active and passive immunization. Immunol Rev 268:88-103. https://doi.org/10.1111/imr.12343.
24. Akiyama K, Ebihara S, Yada A, Matsumura K, Aiba S, Nukiwa T, Takai T. 2003. Targeting apoptotic tumor cells to Fc gamma R provides efficient and versatile vaccination against tumors by dendritic cells. J Immunol 170:1641-1648. https://doi.org/10.4049/jimmunol.170.4.1641.
25. Sallusto F, Lanzavecchia A. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109-1118. https://doi.org/10.1084/jem.179.4.1109.
26. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, Saito T, Verbeek S, Bonnerot C, Ricciardi-Castagnoli P, Amigorena S. 1999. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 189: 371-380. https://doi.org/10.1084/jem.189.2.371.
27. Song H, Nie X, Basu S, Singh M, Cerny J. 1999. Regulation of VH gene repertoire and somatic mutation in germinal centre B cells by passively administered antibody. Immunology 98:258-266. https://doi.org/10.1046/j.1365-2567.1999.00874.x.
28. Aydar Y, Sukumar S, Szakal AK, Tew JG. 2005. The influence of immune complex-bearing follicular dendritic cells on the IgM response, Ig class switching, and production of high affinity IgG. J Immunol 174: 5358-5366. https://doi.org/10.4049/jimmunol.174.9.5358.
29. Wu Y, Sukumar S, El Shikh ME, Best AM, Szakal AK, Tew JG. 2008. Immune complex-bearing follicular dendritic cells deliver a late antigenic signal that promotes somatic hypermutation. J Immunol 180:281-290. https://doi.org/10.4049/jimmunol.180.1.281.
30. Allen CD, Cyster JG. 2008. Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function. Semin Immunol 20:14-25. https://doi.org/10.1016/j.smim.2007.12.001.
31. Roopenian DC, Akilesh S. 2007. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715-725. https://doi.org/10.1038/nri2155.
32. Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, Petkova S, Avanessian L, Choi EY, Shaffer DJ, Eden PA, Anderson CL. 2003. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 170: 3528-3533. https://doi.org/10.4049/jimmunol.170.7.3528.
33. Mann JK, Ndung'u T. 2015. HIV-1 vaccine immunogen design strategies. Virol J 12:3. https://doi.org/10.1186/s12985-014-0221-0.
34. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG. 2001. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276:6591-6604. https://doi.org/10.1074/jbc .M009483200.
35. Lu L, Palaniyandi S, Zeng R, Bai Y, Liu X, Wang Y, Pauza CD, Roopenian DC, Zhu X. 2011. A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection. J Virol 85:10542-10553. https://doi.org/10.1128/JVI .05441-11.
36. Montefiori DC. 2009. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol 485:395-405. https://doi.org/10.1007/978-1-59745-170-3-26.